e5ae4a47-9a0d-4a70-a7be-40bddeb3d017
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 84
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.620
- ALLOGRAFT_REJECTION+0.470
- MTORC1_SIGNALING+0.460
- OXIDATIVE_PHOSPHORYLATION+0.460
- PROTEIN_SECRETION+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- CHOLESTEROL_HOMEOSTASIS+0.360
- COMPLEMENT+0.350
- ANDROGEN_RESPONSE+0.340
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.390
- MYC_TARGETS_V2-0.250
- KRAS_SIGNALING_DN-0.200
- APICAL_SURFACE-0.150
- HEDGEHOG_SIGNALING-0.110
- NOTCH_SIGNALING-0.060
- APICAL_JUNCTION-0.030
- BILE_ACID_METABOLISM+0.010
- ESTROGEN_RESPONSE_EARLY+0.020
- MYOGENESIS+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02087 | — | cohortA1 | 0.893 |
| 2 | 53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D | — | — | 0.875 |
| 3 | TCGA-E7-A7DV-01A-11R-A33J-07 | — | — | 0.860 |
| 4 | C3L-00913 | — | cohortA4 | 0.857 |
| 5 | TCGA-18-3415-01A-01R-0980-07 | — | cohortSQ2 | 0.857 |
| 6 | 49df6599-2159-457c-a94f-980cab788dbf | — | — | 0.856 |
| 7 | SJEPD031215_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.852 |
| 8 | f5174c29-918d-4ad9-bd44-c94463396414 | — | — | 0.851 |
| 9 | SRR10900566 | — | — | 0.850 |
| 10 | BS_XF0ZX2B3 | Supratentorial Ependymoma | — | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.620 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.270 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |